Mnkd | search
Click here to view Mnkd news from 60+ newspapers.
Bookmark or Share- Home | MannKind MNKD Message BoardAll About MNKD - 33 Viewing. Discuss MannKind and its stock (news, fundamentals) 6,713: 174,976: Exchange of Convertible Notes for Stock & Cash by casualinvestor Dec 19, 2024 15:02:49 GMT -5: MNKD Product Script Counts and Other Metrics. This is the place for tabulation and commentary on the script counts formulary adoption, and other metrics ...
- All About MNKD | MannKind MNKD Message Board - ProBoardsMessage board for discussion of MNKD, MannKind Corporation. MannKind MNKD Message Board. Skip Navigation.
- MannKind Successfully Completes Phase 1 Trial of NintedanibDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the successful completion of its first-in ...
- Is a MNKD buyout likely? | MannKind MNKD Message BoardFinally, B-I could consider a buyout of MNKD. B-I has been reasonably active in the M&A space with 15 acquisitions since 1997 with 8 of the 15 in the last 4 years. Most of the acquisition amounts aren't disclosed but the publicly disclosed amounts total more than $12B. B-I could conceivably offer a buyout valuation of $3B.
- 2024 upcoming catalysts | MannKind MNKD Message BoardMessage board for discussion of MNKD, MannKind Corporation. I assume they're referring to a balance sheet accounting for the amount of cash MannKind received from Sagard in return for MannKind assigning 10% of their 10% (net 1%) of royalties from United Therapeutics for sale of Tyvaso DPI that was developed and is manufactured by MannKind.
More
